Compass Therapeutics Investor Presentation Deck
Secondary Endpoints: PFS and OS (as of Nov 9, 2022)
Median OS: NA (12.5-NA)
●
Median PFS: 9.40 m (5.4-11.1)
A 1.0
Survival Probability
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
0
All
T
1
2
2nd line
COMPASS
THERAPEUTICS
3
4 5
3rd line
6
7 8 9
10 11 12 13 14
Progression Free Survival (months)
Number at risk
All 24 23 21 20 17 17 10 10 10 10 7 5 2 2 2
2nd line 11 11 10 9
9
9
1 1
3rd line 13 12 11
11
8 8
1
155
155
055
055
122
Group
All
2nd line
3rd line
21
2
5 3 1 1
15 16
2
1
1
2
1
1
Median (95% CI)
9.4(5.4-11.1)
T
17
1
+ Censored
1
0
10.0(5.1-NA)
5.5(3.6-11.1)
18
1
1
T
19 20
0
0
B
Survival Probability
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
●
—
All
0 1
- 2nd line
T
2 3
T
4
5
-
T
6
Number at risk
All
24 24 23 21 21 21 20
2nd line 11 11 11 11 11 11 11
3rd line 13 13 12 10 10 10
3rd line
7 8 9 10 11 12 13 14 15 16
Overall Survival (months)
19 19 19 17 16 12
10 10 10 9 8 5
8
8
7
Group
All
2nd line
3rd line
9 9 9 9
835
633
532
+ Censored
Median(95% CI)
12.5(10.9-NA)
11.7(9.1-NA)
12.9(5.3-NA)
17 18
2 1
1 1
1 0
1
1
19 20
0
0
%
20View entire presentation